Related Experiment Videos
Carbamazepine versus valproate monotherapy for epilepsy
A G Marson1, P R Williamson, J L Hutton
1University Department of Neurological Science, Room 2.30 - Clinical Science Centre for Research & Education, Lower Lane, Liverpool, Merseyside, UK, L9 7LJ. TMarson@compuserve.com
The Cochrane Database of Systematic Reviews
|July 25, 2000
Summary
This review found limited evidence supporting carbamazepine for partial epilepsies and no clear evidence for valproate in generalized epilepsies. Patient misclassification may have impacted epilepsy treatment outcomes.
Area of Science:
- Neurology
- Pharmacology
Background:
- Carbamazepine and valproate are first-line treatments for epilepsy.
- Clinical belief favors valproate for generalized and carbamazepine for partial epilepsies, despite limited RCT evidence.
Purpose of the Study:
- To compare the efficacy of carbamazepine and valproate monotherapy for epilepsy.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) using individual patient data.
- Outcomes included time to treatment withdrawal, 12-month remission, and time to first seizure.
- Analysis employed stratified Logrank tests with Hazard Ratios (HR) and tested for treatment-epilepsy type interaction.
Main Results:
- Data from 1265 patients across five trials showed no significant overall difference in treatment withdrawal, 12-month remission, or time to first seizure.
- A significant interaction between treatment and epilepsy type was found for time to first seizure.
- Potential misclassification of epilepsy types in adults was noted.
Conclusions:
- Some evidence supports carbamazepine for partial epilepsies, but evidence for valproate in generalized epilepsies is insufficient.
- Confidence intervals are too wide to confirm treatment equivalence.
- Patient misclassification may have confounded results, highlighting the need for careful trial design.